NCT05037929

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1,334 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 40 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	Astegolimab	Participants will receive SC astegolimab Q2W or Q4W.
DRUG	Placebo	Participants will receive SC placebo Q2W.

Timeline

• Start date: 2021-10-05
• Primary completion: 2025-02-24
• Completion: 2025-07-07
• First posted: 2021-09-08
• Last updated: 2026-02-25

Locations

181 sites across 24 countries: United States, Argentina, Australia, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Hong Kong, Israel, Mexico, Netherlands, New Zealand, Peru, Poland, Romania, South Africa, South Korea, Spain, Sweden, United Kingdom

Regulatory

• FDA-regulated drug study